Not So Different: A Podcast from The Center for Biosimilars
Not So Different: a Podcast from The Center for Biosimilars
158 episodes
1 month ago
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
All content for Not So Different: A Podcast from The Center for Biosimilars is the property of Not So Different: a Podcast from The Center for Biosimilars and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
S7 Ep6: All Things Biosimilars: How Streamlined CES Rules Could Shift the Market
Not So Different: A Podcast from The Center for Biosimilars
21 minutes
1 month ago
S7 Ep6: All Things Biosimilars: How Streamlined CES Rules Could Shift the Market
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
Not So Different: A Podcast from The Center for Biosimilars
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
